AYTUAYTUHealthcare · Drug Manufacturers - Specialty & Generic

AYTU Stock Forecast: Aytu Biopharma, Inc. Price Predictions for 2026-2027

Last close, 18 Nov 2026
$2.66
0.00% on the day

The 3 Wall Street analysts covering Aytu Biopharma, Inc. hold a median 12-month price target of $8.85 — +232.7% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 96 of 100 as at 17 Nov 2026 — among the strongest tenth. Here, the model and the Street point the same way.

Market cap
$28.9M
Ticker Nerd rank
96/ 100
Median analyst target
$8.85
Analysts covering
3
Revenue$12.4M−32.7% y/y
Operating income−$4.1M
Net income−$5.6M
Free cash flow−$4.2M
Quarterly, 8 quarters to 31 Mar 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
+47.0%
1M
+30.4%
YTD
+2.3%
1Y
+31.7%
From 52W high
−8.3%
From 52W low
+49.4%
$1.78
$2.90
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

AYTU stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Aytu Biopharma, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 17 Nov 2026
96/ 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Accruals
94
Volatility
90
Value
85
Size
84
Momentum
78
Issuance
70
Quality
69
Growth
61
Revisions
46

Accruals (94): Reported profit is backed by cash, and the company is not expanding recklessly.

Revisions (46): Analysts have, on balance, been cutting their forecasts.

Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.

Wall Street

AYTU stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on AYTU, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0.00$5.00$10.00$15.00Jan 26Apr 26Jul 26Oct 26AYTUHigh $15.00Median $8.85Low $2.70

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says3 analysts
1 Buy2 Hold0 Sell
Low $2.70Median $8.85High $15.00

The green dot is the last close — the median target sits +232.7% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 2 moved their price target up and 3 moved it down.

DateFirmActionRatingTarget
17 Nov 2026Lake StreetDowngradeHold$2.70
17 Nov 2026Maxim GroupDowngradeHold—
30 Sept 2026Ascendiant CapitalMaintainsBuy$15 → $15
11 June 2026Ascendiant CapitalMaintainsBuy—
11 June 2026Ascendiant CapitalMaintainsBuy$14 → $15
10 Dec 2025Ascendiant CapitalMaintainsBuy—
25 Sept 2025Ascendiant CapitalMaintainsBuy—
25 Sept 2025Maxim GroupMaintainsBuy—
1 July 2025Lake StreetInitiatesBuy—
30 June 2025Ascendiant CapitalInitiatesBuy—
9 Aug 2023Maxim GroupInitiatesBuy—
31 May 2023HC Wainwright & Co.ReiteratesBuy—
21 July 2022HC Wainwright & Co.MaintainsBuy$11 → $6.00
17 May 2022Cantor FitzgeraldMaintainsOverweight$11 → $5.00
28 Apr 2022HC Wainwright & Co.MaintainsBuy$24 → $11
30 Mar 2021Cantor FitzgeraldInitiatesOverweight—
25 Nov 2020HC Wainwright & Co.InitiatesBuy—
25 Nov 2020Northland SecuritiesInitiatesOutperform—
29 May 2020HC Wainwright & Co.InitiatesBuy—
22 Oct 2018Northland SecuritiesInitiatesOutperform—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

AYTU appears in the Radar on the weeks it earns a place.

  • Market Radar, every Monday: the week's biggest rank moves across ~4,600 US stocks, and the reason for each.
  • The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.

Free. Unsubscribe any time. Privacy

The AI build-out map
PDF
  • AI cloud capacity

    MSFTAMZNGOOGLORCL

  • AI chips

    NVDAAVGOAMDMU

  • AI networking and servers

    ANETDELLLITECRDO

  • Data centre power

    VRTCEGGEVVST

Performance

AYTU vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 18 Nov 2026, Aytu Biopharma, Inc. returned +31.7% against +12.2% for the S&P 500, dividends included.

AYTU vs S&P 500, last 12 monthsTotal return, rebased to 100
90100110120130140Jan 26Apr 26Jul 26Oct 26AYTUS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

AYTU analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingThis fiscal year
Analysts raising
0
Analysts cutting
2
Fundamentals

Aytu Biopharma, Inc. (AYTU) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−1.2×

Cheaper than 83% of US stocks

Price / sales
0.5×

Cheaper than 86% of US stocks

Price / book
0.9×

Cheaper than 81% of US stocks

EV / EBITDA
−3.1×

Cheaper than 77% of US stocks

Growth & margins
Revenue growth (YoY)
6.9%

Higher than 45% of US stocks

Earnings growth (YoY)
−32.7%

Higher than 16% of US stocks

Gross margin
61.2%

Higher than 74% of US stocks

Operating margin
−18.4%

Higher than 23% of US stocks

Net margin
−34.3%

Higher than 14% of US stocks

Returns & dividend
Return on equity
−73.4%

Higher than 21% of US stocks

Return on assets
−6.0%

Higher than 32% of US stocks

Dividend yield
0.0%

Higher than 1% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Aytu Biopharma, Inc. (AYTU) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Aytu Biopharma, Inc. has a market value of $28.9M and an enterprise value of $19.9M.

  • Revenue in the twelve months to 31 Mar 2026: $56.6M. The latest quarter grew 6.9% year on year.

  • Net income over the same four quarters: −$34.1M, a −60.2% net margin.

  • Free cash flow in the twelve months to 31 Mar 2026: −$1.4M, after $34K of capital spending.

  • Shares outstanding: 10.7M.

  • Trailing P/E: −1.2×; forward P/E: 17.1× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Forward dividend yield: 0.00%, paying out 0% of earnings.

  • Aytu Biopharma, Inc. employs 75 people — $755K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 31 Mar 2026 · market figures as at 18 Nov 2026

Data provided by Twelve Data

Peers

AYTU vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelDrug Manufacturers - Specialty & Generic
CompanyMarket capTKN rank
AYTUAytu Biopharma, Inc.$28.9M96
SCYXSCYNEXIS, Inc.$28.3M36
RMTIRockwell Medical, Inc.$26.1M78
TXMDTherapeuticsMD, Inc.$22.1M82
CPHIChina Pharma Holdings, Inc.$21.5M48
IXHLIncannex Healthcare, Inc.$20.8M50
SHPHShuttle Pharmaceuticals Holdings, Inc.$20.5M20

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Aytu Biopharma, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest AYTU news & analysis

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Aytu BioPharma, Inc. (Nasdaq – AYTU), Rapid Micro Biosystems, Inc. (Nasdaq – RPID), Advantage Energy Ltd. (OTC – AAVVF), Canaccord Genuity Group Inc. (OTC – CCORF)

GlobeNewsWire · 17 Nov 2026neutral

Brodsky & Smith announced an investigation involving Aytu BioPharma, Inc. and three other companies. The notice invites shareholders to contact the firm to discuss the investigation.

Why it matters — AYTU shareholders may want to note the announced investigation and the firm’s invitation to discuss it.

AYTU Shareholder Alert: Ademi LLP Investigates Whether Buyout Fairly Values Aytu Biopharma, Inc.

GlobeNewsWire · 17 Nov 2026negative

Ademi LLP said it is investigating whether Rosemont Pharmaceuticals’ proposed acquisition of Aytu Biopharma fairly values public shareholders. The excerpt says shareholders would receive $2.70 per share in a tender offer and notes questions about insider benefits and restrictions on competing offers.

Why it matters — AYTU watchers may want to note the investigation’s scrutiny of the proposed deal price and the board’s handling of shareholder interests.

Aytu BioPharma, Inc. (AYTU) Reports Q1 Loss, Beats Revenue Estimates

Zacks Investment Research · 16 Nov 2026negative

Aytu BioPharma reported a quarterly loss of $0.20 per share, compared with the Zacks Consensus Estimate of a $0.10 loss and a loss of $0.08 per share a year earlier. The headline says the company beat revenue estimates, but the excerpt provides no revenue figures.

Why it matters — AYTU watchers may note that the reported quarterly loss was larger than the consensus estimate and the year-ago loss.

FAQ

Frequently asked questions about AYTU stock

What is the AYTU stock price forecast for 2026-2027?

The 3 Wall Street analysts covering Aytu Biopharma, Inc. have a median 12-month price target of $8.85, with estimates ranging from $2.7 to $15. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is AYTU stock a buy right now?

Of the 3 analysts covering Aytu Biopharma, Inc., 1 rate it a Buy, 2 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Aytu Biopharma, Inc. 96 out of 100 across roughly 4,600 US stocks as at 17 Nov 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank AYTU?

As at 17 Nov 2026, Aytu Biopharma, Inc. ranks 96 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Accruals (94 of 100).

Will AYTU stock go up?

No one can know that. What the data says: the median 12-month target from 3 analysts implies +232.7% from the last close, and Ticker Nerd's factor model ranks Aytu Biopharma, Inc. 96 out of 100 as at 17 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the AYTU stock forecast for 2030?

No analyst covering Aytu Biopharma, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for AYTU are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $2.7 to $15 over the next 12 months.

How has AYTU stock performed over the past year?

Aytu Biopharma, Inc. returned +31.7% over the 12 months to 18 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Aytu Biopharma, Inc. do?

Aytu BioPharma, Inc. is a specialty pharmaceutical company focused on prescription therapeutics and consumer health products.

What is the latest news on AYTU?

The most recent item we track (GlobeNewsWire, 17 Nov 2026): "BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Aytu BioPharma, Inc. (Nasdaq – AYTU), Rapid Micro Biosystems, Inc. (Nasdaq – RPID), Advantage Energy Ltd. (OTC – AAVVF), Canaccord Genuity Group Inc. (OTC – CCORF)". Brodsky & Smith announced an investigation involving Aytu BioPharma, Inc. and three other companies. The notice invites shareholders to contact the firm to discuss the investigation.

Company

About Aytu Biopharma, Inc.

Aytu BioPharma, Inc. is a specialty pharmaceutical company focused on prescription therapeutics and consumer health products. Aytu BioPharma primarily serves patients with complex central nervous system conditions, with products used in the treatment of major depressive disorder and attention deficit-hyperactivity disorder. Its current portfolio also includes medicines for allergic conditions and fluoride-based pediatric supplement products for infants and children. The company markets its prescription products through third-party channels and also offers consumer health items directly to consumers. Based in Denver, Colorado, Aytu BioPharma operates as a commercial-stage healthcare company with a portfolio aimed at addressing ongoing medical needs across psychiatry, pediatrics, and supportive care.

CEO Mr. Joshua R. Disbrow · 75 employees · United States · https://aytubio.com